Practice Updates in HR+ Breast Cancer

A panel of breast cancer experts review clinical cases in hormone receptor-positive breast cancer, focusing on the optimal treatment approaches for patients and updates on key clinical trial data.

EP. 1: Case 1: High-Risk, HR+/HER2- Early-Stage Breast Cancer

February 28th 2022

Experts in breast cancer review the case of a 54-year-old postmenopausal woman with stage IIB, high-risk, HR+ early-stage breast cancer and discuss factors to consider when assessing risk for systemic occurrence.

EP. 2: Case 1: MonarchE Study in High-Risk, HR+ Early Breast Cancer

February 28th 2022

Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’ Shaughnessy, MD, review the study design and clinical implications from the monarchE study for high-risk, HR+ early breast cancer.

EP. 3: Case 1: Using Adjuvant Abemaciclib for High-Risk HR+ Early Breast Cancer

February 28th 2022

Joyce O’ Shaughnessy, MD; Sunil Badve, MD, FRCPath; and Massimo Cristofanilli, MD, FACP, consider the role of adjuvant abemaciclib plus endocrine therapy for the treatment of patients with high-risk, node-positive, HR+ early breast cancer.

EP. 4: Case 1: Role of Ki67 Testing in HR+ Early Breast Cancer

February 28th 2022

Sunil Badve, MD, FRCPath, and Heather McArthur, MD, evaluate best practices around Ki67 assessment when approaching treatment for HR+ early breast cancer.

EP. 5: Case 1: Clinical Implications From MonarchE in HR+ Early Breast Cancer

February 28th 2022

Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’Shaughnessy, MD, share insight on applying data presented from the monarchE study and the use of adjuvant abemaciclib in clinical practice for high-risk, HR+ early breast cancer.

EP. 6: Case 2: HR+ High-Risk Breast Cancer

March 7th 2022

Experts in breast cancer review the case of a 42-year-old woman with grade 2, node-positive invasive ductal carcinoma and discuss updated data from the RxPONDER trial on adjuvant chemotherapy benefit in premenopausal women.

EP. 7: Case 2: SABCS 2021 Updates on SOFT and TEXT Trials for HR+ Breast Cancer

March 7th 2022

Joyce O’Shaughnessy, MD, leads a discussion on SABCS 2021 updates from the SOFT and TEXT trials for premenopausal women with HR-positive breast cancer.

EP. 8: Case 2: Recommendations for Approaching Treatment of HR+ Breast Cancer

March 7th 2022

A panel of breast cancer experts share recommendations for adjuvant chemotherapy and endocrine therapy for a patient with HR-positive breast cancer and discuss approaches to toxicity management to increase adherence to therapy.

EP. 9: Case 3: POETIC and ADAPT Trials in HR+ High-Risk Breast Cancer

March 14th 2022

Joyce O’Shaughnessy, MD, reviews the case of a 42-year-old woman with node-positive, HR-positive high-risk breast cancer and discusses clinical data from the POETIC and ADAPT clinical trials.

EP. 10: Case 3: Role of Preoperative Endocrine Therapy in HR+ High-Risk Breast Cancer

March 14th 2022

Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’Shaughnessy, MD, comment on the role of preoperative endocrine therapy in HR-positive high-risk breast cancer.